[Transfer] Hengdian creature completed tens of millions of angel round financing, cracking the research and development of excitement antibody drugs

[Transfer] Hengdian creature completed tens of millions of angel round financing, cracking the research and development of excitement antibody drugs

Source: arterial network

It is learned that recently, Zhongshan Hengdian Biopharmaceutical Co., Ltd. (hereinafter referred to as "Hengdian Biological") announced the completion of tens of millions of yuan of angel round financing, which was led by Zhongshan Health Technology Industry Base Investment Management Co., Ltd. Qingyun followed.

Established in Zhongshan, Guangdong in December 2021, it is committed to using advanced and unique excitement antibody screening, optimization and assessment of core technology platforms, and develops exciting antibody drugs with a new type of drug potential. The Hengdian Biotechnology Platform is a representative of the new generation of excitement "optimized monoclonal anti -resistance" technology. The developed excitement antibody has a monoclonal form and a dual -resistant function, which not only achieves the order of the order of excitement, but also enhances the targeted tumor tissue targetedness Essence The new -generation excitement "optimization monoclonal" technology of Hengdi Bio has the simplest, natural and intellectual property protection solution for the development of excitement antibodies. At present, Hengdian creatures have deployed multiple pipelines, and the most leading pipelines will be declared IND in 2023.

Dr. Li Fubin, the founder and chief scientist of Hengdi Bio, said: "Excal -in antibody is the core means to accurately activate the key signal of the body's immune, which can provide patients with 'positive energy'. Treatment and cell therapy complement each other is the most anticipated breakthrough in the medical field. Although the research and development of excitement antibodies has been relatively slow in the past two decades, the development of excitement antibody development is clear. We have taken the road to innovation. Our research has been focusing on the impact of different structural modules of antibodies on excitement activity in the past ten years. We have a new understanding of excitement antibodies. On the basis of this The ideas and solutions have established a new generation of optimization technology. Hengdian creature hopes to achieve the leap from original technology to original innovation medicine. The realization of this vision is inseparable from entrepreneurial partners. Trust and support. "

Yan Xiaohua, co -founder and CEO of Hengdi Bio, said: "The market prospect of the excitement antibody is broad. Once a breakthrough is made, it can be used alone, and it can be used alone, with traditional therapy such as chemotherapy and chemotherapy. Used and played a synergy, it is expected to become a "broad -spectrum anticancer drug", changing the ending of the treatment of a variety of refractory physical tumors. This round of financing will accelerate the development process of constant organisms and support us to push the core pipeline faster. To clinical, benefit patients with global tumors. Hengdi creatures set off from the Health Base of Zhongshan National Health Base. They are confident that under the all -round empowerment of health bases, Tengye Venture Capital, and good medical friends, they will create in the field of excitement antibody drugs in the field of excitement antibody drugs. R & D platform with international competitiveness, make a '0 to 1' innovation. "

Yang Quan, the person in charge of the investment management of Zhongshan Health Technology Industry Base Base, said: "Spectering antibody is the forefront of tumor immunotherapy. Hengdang creatures, as the cutting -edge enterprises developed by excitement antibodies, gathered the top scientific research in this field. Talent, based on the excellent manifestation of clinical trials of the company's excitement antibody CS01, coupled with the original research results achieved by the core team in the field of excitement antibody, we believe that Hengdi may become a leader in the research and development of excitement antibody drugs. The layout cultivates the frontiers of biomedicine's frontier research and development, and I look forward to the growth of Hengdian creatures growing into another 'Kangfang Biological' in the health base park. "

Gao Wei, a partner of Tengye Investment, said: "Tengye Venture Capital is very happy to become an entrepreneurial partner of Hengdi creatures. Immunotherapy has become a star of tumor treatment with its unprecedented excellent effect. How to improve the effectiveness of immunotherapy has become an important proposition, and it is also an important direction for many pharmaceutical companies to chase. Similar to immunosuppressants, immune excitement activates the immune system and improves tumor inhibitory micro -environment. It is expected to enter the current immunosuppressure agent The invalid areas benefit more patients. The founders of Hengdian creatures have deeply cultivated the excitement antibody field for more than ten years, and a unique and advanced antibody generation and screening platform has been established. Their research results lead the direction of excitement antibodies. Globally, pharmaceutical companies have repeatedly pushed immune excitement to the clinic, but this field is still in the start and accumulation stage. We are optimistic about the deep development of Hengdi creatures in this field and stand on the shoulders of past clinical information. ', Climb the peak of immune excitement in one fell swoop. "

Tengye Venture Capital focuses on the early investment of high -tech innovation enterprises. It has managed 7 funds and has invested nearly 40 enterprises. Tengye Venture Capital has a professional investment management team with a deep background in the industry. In emerging industries, it is found to find outstanding teams and startups with core technologies and products, and help enterprises grow with rich industry resources. Investment areas include biomedicine and medical health, TMT, new energy and energy conservation and environmental protection, advanced manufacturing and high -end equipment. Star cases in the field of medical and health include Gan Li Pharmaceutical, Liuhe Ningyuan, Pai Zhen Biological, Jiabao Renhe, Kim Shi Biology, Udao Biology, Kutu Medicine, Wide Pharmaceutical, Zhongjing Pukang, Hashimi Biology, Zhenmai Biology, Love, Love, Love Qiao Medical, Noesland, etc.

Zhongshan Health Technology Industry Base Investment Management Co., Ltd. (hereinafter referred to as "Health Base Investment Company") is a wholly -owned subsidiary of Zhongshan Health Base Group Co., Ltd. (hereinafter referred to as "Health Base"). (Limited partnership) fund manager. The health base investment company is closely cooperated with the parent company's health base to form a professional financial service team to provide full services for sub -funds and their investment projects. Members of the core management and operation team of the health base investment company have been deeply cultivating the field of health industry for many years. They have professional judgment capabilities in the health industry projects, rich experience in investment promotion and asset management, and also have equity investment experience. Since the establishment of the Health Base Investment Corporation, it has made outstanding contributions to the industrial investment and capital operation of the health base by participating in the establishment of a number of large health industry funds and direct investment.

A good medical friend is a comprehensive multinational medical and health industry group. It has a leading domestic cross -border medical platform. Cross -border medical services integrated in precision medical care. In the field of biomedicine, good medical friends have invested in innovative pharmaceutical projects such as Xu Nuo Pharmaceutical, Hengdi Biology, and Junrui Biological, which will further improve the layout of the medical ecosystem of the medical friends and benefit more tumor patients.

Disclaimer: This article is the content of Yaozhi.com, and the copyright of the pictures and text belongs to the original author. The purpose of reprinting is to pass more information, which does not represent the viewpoint of this platform. If the content, copyright and other issues are involved in the work, please leave a message on this platform, and we will delete it as soon as possible.

- END -